• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Dec. 12, 2022

View Archived Issues
10-28-Boston-Science_Global-Headquarters_Marlborough,-Mass

Boston Scientific bids $523M for majority stake in Acotec

Boston Scientific Corp. offered $523 million in cash for 65% of Acotec Scientific Holdings Ltd., a manufacturer of vascular intervention devices. The acquisition would significantly expand Boston Scientific’s presence in China, which the company expects to account for about 25% of the global med-tech market by the end of the decade. The transaction is expected to close in the first half of 2023, subject to shareholder approval. The offer price of HK$20 or US$2.57 per share represents a premium of more than 31% over its close on Friday, Acotec reported. Read More

Natus buys Micromed to expand footprint with neurodiagnostic and neuromonitoring devices

Natus Medical Inc. entered into a definitive agreement to acquire EU-based neurophysiology solution provider Micromed Group SpA. The transaction is expected to close in early 2023, subject to regulatory approvals from the Italian Council of Ministers’ Presidency and the French Ministry of Economy and Finance. Full terms of the transaction have not been disclosed. “The idea behind this acquisition is to provide a single portfolio of neurodiagnostic and neuromonitoring products in the EU and the whole world,” Thomas Sullivan, CEO of Natus Medical, told BioWorld. Read More
Dollar sign at center of maze

GE Healthcare reveals strategic plans, financial targets as independent company

Less than a month from its launch as a stand-alone business on Jan. 4, 2023, GE Healthcare Holding LLC provided a glimpse of its future plans for growth and anticipated financials for investors. The soon-to-be-launched company is hardly waiting until its spinoff to look for tuck-in acquisitions to boost sales and profitability and add new capabilities for customers and patients. Read More

Olive seeking $10M in A round for urine analysis system

Olive Diagnostics Pvt. Ltd. is looking to raise $10 million in a series A funding round to extend sales and marketing activities, after getting CE approval for its urine analysis device that mounts on any toilet. Among other parameters the device, Olive KG, can measure red blood cells, proteins, nitrates, pH levels volume, pressure and frequency of urination. Read More
heart-cardio-data.png

Cytokinetics hoping for good adcom review of heart failure drug

What could be Cytokinetics Inc.’s first approved drug will take center stage Dec. 13 at a meeting of the U.S. FDA’s Cardiovascular and Renal Drugs Advisory Committee. But judging from the FDA’s briefing document for the meeting, the spotlight on the heart failure drug, omecamtiv mecarbil, could be harsh. Read More

Med-tech gainers and losers for Dec. 5-9, 2022

The top 10 med-tech stock gainers and losers for the week. Read More

Appointments and advancements for Dec. 12, 2022

New hires and promotions in the med-tech industry, including: Hologic. Read More

Financings for Dec. 12, 2022

Med-tech firms raising money in public or private financings, including: Monarch Medical Technologies, Semler Scientific. Read More

In the clinic for Dec. 12, 2022

Clinical updates, including trial initiations, enrollment status and data readouts and publications: C2n Diagnostics, Exact Sciences. Read More

Other news to note for Dec. 12, 2022

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Avita, Biotricity, Clearpoint Neuro, Elekta, ICU Medical, Meridian Bioscience, Mindleap, Mydecine Innovations, Pangenomic Health, SD Biosensor, Signati Medical, Smiths Medical, Superiorvas. Read More

Regulatory actions for Dec. 12, 2022

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Irras, RF Medical. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 24, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe